Voluntis, AstraZeneca to Test Mobile App Supporting Patients with Platinum-Resistant Ovarian Cancer

Voluntis, AstraZeneca to Test Mobile App Supporting Patients with Platinum-Resistant Ovarian Cancer
Voluntis and AstraZeneca have extended their partnership to evaluate a mobile app, called eCO (eCediranib/Olaparib), to help women with platinum-resistant ovarian cancer report and manage their side effects. The approach is being developed for women receiving a combination of cediranib plus Lynparza (olaparib), and will be tested in the GY005 Phase 2/3 clinical trial (NCT02502266), which started in 2015 and

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *